Medibank Backs Emyria with Multi-Year Funding Agreement for Depression Program.

Emyria Limited (ASX: EMD) has secured a landmark multi-year agreement with Medibank Private Ltd to fund treatment for eligible patients enrolled in its Treatment-Resistant Depression (TRD) program at Perth Clinic. This marks the first time a major Australian health insurer has committed to funding a psychotherapy-led TRD program, reducing financial barriers and improving access for patients who do not respond to conventional treatments. The initiative builds on Medibank’s existing support for Emyria’s PTSD program, which is already delivering positive outcomes.

With both PTSD and TRD programs now insurer-funded, Emyria strengthens its position as a leader in delivering innovative, psychiatrist-led mental health treatments. The company’s scalable Empax Model, valued between AU$20,000 and AU$30,000 per patient course, highlights significant growth potential as demand rises. This agreement demonstrates strong validation of Emyria’s data-driven approach and sets the stage for national expansion, offering lasting benefits for patients and the healthcare system.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com